BUILDS BIO+

NEIGHBORHOOD SPOTLIGHT SERIES

NYC'S WEST END LABS: THE NEXT MAJOR LIFE SCIENCE AND INNOVATION HUB

WELCOME REMARKS

NANCY J KELLEY

President and CEO, **Nancy J Kelley & Associates**

Founding Member and Steering Committee **Builds Bio+**

MITCHEL SIMPLER

Managing Partner Emeritus, **JB&B**

Founding Member and Steering Committee, **Builds Bio+**

THANK YOU TO OUR HOSTS

THANK YOU TO OUR FOUNDING MEMBERS

AND OUR SIGNATURE MEMBER

THANK YOU TO OUR CORPORATE MEMBERS

AGENDA

8:15 AM – 9:00 AM: Networking Breakfast

9:00 AM: Welcome Remarks

- **Nancy J Kelley**, Nancy J Kelley & Associates and Builds Bio+
- **Mitchel Simpler**, JB&B and Builds Bio+

9:05 AM: Taconic & Graviton Fireside Chat

- **Matt Malone,** Elevate Research Partners/ Taconic Partners
- **Sam Waksal**, Graviton Bioscience Corporation

9:25 AM: A Discussion with the Firms Transforming Midtown West Into A Burgeoning Innovation Hub

Moderator: Nancy J Kelley,
Nancy J Kelley & Associates and Builds Bio+

- **Matt Malone**, Elevate Research Partners/ Taconic Partners
- **Paul Apollonio**, The Georgetown Company

10:00 AM: Tenant Perspectives – Presentations from the West End's Leading Life Science Organizations

Moderator: Nancy J Kelley,
Nancy J Kelley & Associates and Builds Bio+

- **Priti Balchandani**,
  Icahn School of Medicine at Mount Sinai
- **Deepak Vashishth**, Rensselaer Polytechnic Institute and Center for Engineering and Precision Medicine
- **Rui Wu,** Graviton Bioscience Corporation

10:45 AM: Closing Networking & Select Tours

TACONIC PARTNERS & GRAVITON BIOSCIENCE FIRESIDE CHAT

SAM WAKSAL
Founder and CEO
Graviton Bioscience Corporation

MATT MALONE
Senior Vice President, Life Sciences
Taconic Partners

A DISCUSSION WITH THE FIRMS TRANSFORMING MIDTOWN WEST INTO A BURGEONING INNOVATION HUB

MATT MALONE
Senior Vice President, Life Sciences
Taconic Partners

PAUL APOLONIO
Managing Director
The Georgetown Company

THE HUDSON RESEARCH CENTER

125 WEST END AVENUE

787 11TH AVENUE

707 11TH AVENUE

Exterior render of 707 11th Avenue at nighttime, courtesy of Goldin Solutions

render of 707 11th Avenue, courtesy of Goldin Solutions

TENANT PERSPECTIVES – PRESENTATIONS FROM THE WEST END'S LEADING LIFE SCIENCE ORGANIZATIONS

RUI WU

Senior VP, Head of Research & Pre-Clinical, Chief CMC Officer **Graviton Bioscience Corporation**

PRITI BALCHANDANI

Professor of Radiology, Neuroscience and Psychiatry, **Icahn School of Medicine at Mount Sinai**

DEEPAK VASHISHTH

RPI Co-Director, **Rensselaer Polytechnic Institute, Center for Engineering and Precision Medicine**

graviton
bioscience

Curing Disease Through Restored Homeostasis

MAY 2024

A Novel Breakthrough Clinical-Stage Solution for Restoring Homeostasis

Company Overview

Founded & led by serial life sciences entrepreneur, Dr. Samuel Waksal (founder of ImClone, Kadmon & MeiraGTX).

Dedicated to addressing critical unmet needs in autoimmune, fibrotic and CNS diseases.

Funded by top-tier institutional investors – Enavate Sciences, Pontifax Venture Capital, Cormorant Asset Management, and marquee strategic collaborators – Sanofi and Ovid Therapeutics.

Best in-class Inhibitor Portfolio

Leading with a best-in-class clinical-stage ROCK2 inhibitor, setting new standards on therapeutic care.

A diverse pipeline showing promise for broad-spectrum applications in autoimmune, fibrotic metabolic & CNS diseases.

Expanding our therapeutic reach with multiple candidates in development, including targeted C6 & DYRK inhibitors.

World Class Leadership & Vision

Our team's expertise extends to groundbreaking treatments across indications, including GvHD, showcasing a deep and unique understanding of ROCK2's therapeutic potential.

Visionary leadership with proven track record of transforming complex scientific insights into successful clinical outcomes, with 6 FDA approved drugs.

Renowned and experienced board of directors, and scientific advisors.

Graviton Bioscience Leadership Team

Samuel Waksal, PhD

Founder & CEO

ImClone Systems Incorporated · Kadmon · MEIRAGTx · Stanford Medicine · Weizmann Institute of Science · Weill Cornell Medicine

Amy Melsaether, MD

Chief Medical Officer

Mount Sinai · UCLA · NYU Langone Health

Rui Wu, PhD

Senior VP, Head of Research & Pre-Clinical

Weill Cornell Medicine · equillibre · MEIRAGTx

Samia Shamim

Head of Bus. Development & Operations

Harvard Business School · Goldman Sachs · NYU STERN

Alexandra Zanin-Zhorov, PhD

Head of Translational Medicine

Kadmon · NYU Langone Health · Weizmann Institute of Science

Justin Stebbing, MD, PhD

Clinical & Scientific Strategy

University of Oxford · Benevolent AI

Julia Balanova

Corporate Communications & Strategy

Benevolent AI · Schonfeld

Jean Kim, PhD

Head of Chemistry

Kadmon · MEIRAGTx

Marquee Strategic Partnerships

Sanofi has made a pivotal equity investment in Graviton Bioscience, forging a dynamic partnership aimed at propelling our innovative selective ROCK2 inhibitors to new heights. This investment is designed to be a long-term engagement, exploring multiple therapeutic areas, particularly within immunology and metabolic syndromes. Together, we are dedicated to enhancing treatment options and improving patient outcomes across the globe.

Graviton has joined forces with Ovid Therapeutics to accelerate the development of novel ROCK2 inhibitors, targeting the treatment of Cerebral Cavernous Malformations (CCMs) and orphan CNS indications. We are charged with advancing these promising candidates through Phase 2 clinical trials. Upon completion, Ovid will spearhead the commercialization efforts, delivering this drug to those affected by CCMs and other orphan CNS diseases.

Graviton has a long-term partnership with the Chinese pharmaceutical company Sino Biopharmaceutical. Sino Biopharmaceutical is working with Graviton on ROCK2 inhibitors. ROCK2 is involved in several diseases including fibrotic, autoimmune and CNS diseases. The company's plan is to move forward in clinical programs with further investigation in 2024.

Graviton and MeiraGTx entered into a licensing agreement to develop products for the treatment and prevention of all ocular diseases . Under this collaboration, MeiraGTx gains access to Graviton's technology to develop and commercialize multiple ophthalmology drug candidates. In exchange, Graviton stands to receive milestone payments and royalties on these therapies. This partnership underscores a shared commitment to advancing innovation in ophthalmic treatments, with the goal of delivering impactful solutions to patients in need.

Graviton Pipeline Summary

Targets Pipeline

ROCK 2 (GV101, GV134, GV119)

ROCK2 is involved in a wide range of cellular functions, from contraction, motility to proliferation. Inhibiting of ROCK2 can be beneficial for a broad variety of indications.

DYRK1

DYRK1 kinases regulate cellular signaling crucial for cellular dormancy, impacting autoimmune diseases like Type 1 diabetes and cancer progression, resistance, and relapse. Targeting DYRK1 offers a novel strategy for treating both conditions.

Anti C6

Our novel monoclonal antibody against C6 prevents the formation of Membrane Attack Complex (MAC) with therapeutic potential in the treatment of neurological diseases.

CD47 Protein

Our CD47 protein binds to SIRP*α* to efficiently inhibit CD47-SIRPα signaling. It has the potential to be active in certain hard-to-treat cancers.

Anti-PD1/IL15

Engineered immune cytokine activates PD1 positive tumor-infiltrating lymphocytes with minimal impact on peripheral natural killer cells and T-cells, enhancing cancer immunotherapy safety and efficacy.



graviton bioscience

Thank you

info@gravitoncorp.com

Creating a NYC ecosystem for new discoveries in engineering medicine

Priti Balchandani, PhD

Professor of Diagnostic, Molecular and Interventional Radiology, Neuroscience and Psychiatry

Associate Director of Biomedical Engineering and Imaging Institute

Director of the Advanced Neuroimaging Research Program

Co-Director of Center for Engineering and Precision Medicine

Icahn School of Medicine at Mount Sinai

Engineering can Transform Medicine

Vision: Applying engineering principles and design concepts to medicine and biology for healthcare to completely change the way diseases are detected, treated, and managed.

Neuroengineering



Vision

Minimally invasive control and regulation of neural circuitry

Immunoengineering



Vision

Engineer immune system to treat cancer and infectious diseases

Reparative and Regenerative Medicine



Vision

On demand personalized tissue repair and regeneration

Three Areas at The Forefront of Engineering and Medicine

Engineering can Transform Medicine

Vision: Applying engineering principles and design concepts to medicine and biology for healthcare to completely change the way diseases are detected, treated, and managed.

Neuroengineering



Vision

Minimally invasive control and regulation of neural circuitry

Immunoengineering



Vision

Engineer immune system to treat cancer and infectious diseases

Reparative and Regenerative Medicine



Vision

On demand personalized tissue repair and regeneration

Three Areas at The Forefront of Engineering and Medicine

Neuroengineering: *Neuroscience and Electrical Engineering enabling targeted treatment of neurological disease*

Wireless Neurostimulation



Akbar Alipour et al.



Imaging, Modeling & Network Analysis



Yael Jacob et al.

Wearable Sensors



Yun Soung Kim et al.

Low Field Accessible MRI

Sairam Geethanath et al.

Neuromodulation



Spencer Brinker et al.

Neuroengineering: *Neuroscience and Electrical Engineering enabling targeted treatment of neurological disease*

Wireless Neurostimulation



Akbar Alipour et al.



Imaging, Modeling & Network Analysis



Yael Jacob et al.

Wearable Sensors



Yun Soung Kim et al.

Low Field Accessible MRI

Sairam Geethanath et al.

Neuromodulation



Spencer Brinker et al.

Advanced Imaging: Multiple Windows Into The Brain











Neuroimaging: Revealing Complex Brain Networks



Neuroimaging: Research Applications



Ultrahigh field Imaging of epilepsy

Planning and guidance of minimally invasive surgery



Functional and structural network and graph theory analysis of psychiatric disorders

Dr. Yael Jacob, Psychiatry

Advancing Engineering Medicine Discoveries: How do we achieve this?

Original Vision: Applying engineering principles and design concepts to medicine and biology for healthcare to completely change the way diseases are detected, treated, and managed.

Co-localized Research Space



Specialized Education



Commercialization

CEPM: Birth of a Center for Collaborative Innovation

NYC Mayor Eric Adams Joined Top Biomedical Researchers to Usher in the **Center for Engineering and Precision** Medicine at Hudson Research Center at 619 West 54th Street

Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai Partner to advance medical research at the life sciences hub

CEPM: Aligned with newly announced initiatives at NIH

New NIH opportunities

NIH National Institutes of Health

ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)

The Advanced Research Projects Agency for Health (ARPA-H) supports the development of high-impact research to drive biomedical and health breakthroughs to deliver transformative, sustainable, and equitable health solutions for everyone.* ARPA-H's mission focuses on leveraging research advances for real world impact.

ARPA-H advances high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity. ARPA-H awardees are developing entirely new ways to tackle the hardest challenges in health. The ARPA model enables visionary Program Managers to tackle a specific problem, working with a range of performers and a variety of

Manu Platt talks about the new NIH Center for Biomedical Engineering Technology Acceleration

The National Institute of Biomedical Imaging and Bioengineering has established a new Center for Biomedical Engineering Technology Acceleration, dedicated to applying engineering principles to biomedical discovery and therapeutics. We talk to the Center's Director Manu Platt about their plans and the focus on diversity, equity, inclusion and accessibility.

Congratulations on being appointed as the Director of the new Center for Biomedical Engineering Technology Acceleration (BETA). What are the aims and objectives of this new National Institutes of Health

interest in bio
seek to becor
have trained
driven physic
medicine in n
neers. The div
also enhance t
bility of the so
of other unde
with disabili
published stu
respectful res
these goals, a
research spa
opportunitie
Representatic

How can bioe

At CEPM, we are creating the "primordial soup" with all the ingredients from which multiple inventions will continue to originate and evolve.

THANK YOU!